Zinc-based radioenhancers to activate tumor radioimmunotherapy by PD-L1 and cGAS-STING pathway

Authors:

Abstract
Radiotherapy and immunotherapy have already become the primary form of treatment for non-small-cell lung cancer (NSCLC), but are limited by high radiotherapy dose and low immune response rate. Herein, a multi-pronged strategy using a radio-immuno-enhancer (ZnO–Au@mSiO2) is developed by inducing tumor cells apoptosis and reprograming the immunosuppressive tumor microenvironment (TME). The radio-immuno-enhancer employed Au as a radiosensitizer, transition Zn ions as immune activators, which not only tremendously enhances the anti-proliferative activity of radiotherapy toward cancer cells, but also activates the immune response with multi-targets to let “exhausted” T cells “back to life” by triggering immunogenic cell death (ICD), immune checkpoint blockade (ICB) that target PD-1/PD-L1 and cGAS-STING under X-ray irradiation with a low dosage. The in vivo results demonstrate desirable antitumor and immunogenic effects of radio-immuno-enhancer-mediated immune activation by increasing the ratio of cytotoxic T cells (CTLs) and helper T cells. This work provides a feasible approach for future development of effective transition metal ion-activated radio-immunotherapeutic agents.
Funding Information
  • the Joint Funds for the innovation of science and Technology, Fujian province (2021Y9022)
  • Open Funds of Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy (NPC2023-01)
  • National Natural Science Foundation of China (82172007, 81771977)
  • the Science Fund for Distinguished Young Scholars of Fujian Province (2021J06007)
  • Key Clinical Specialty Discipline Construction Program of Fujian,P.R.C ([(2022)884#])

This publication has 57 references indexed in Scilit: